Drug
Macitentan 10mg
Macitentan 10mg is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Phase Distribution
Ph phase_3
2
50%
Ph phase_2
2
50%
Phase Distribution
0
Early Stage
2
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (50.0%)
Phase 32 (50.0%)
Trials by Status
withdrawn125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension
NCT04780932
completedphase_2
Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
NCT02554903
withdrawnphase_3
Macitentan to Prevent PRVO
NCT05946811
completedphase_3
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
NCT01474109
Clinical Trials (4)
Showing 4 of 4 trials
NCT04780932Phase 2
Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension
NCT02554903Phase 2
Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
NCT05946811Phase 3
Macitentan to Prevent PRVO
NCT01474109Phase 3
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4